Table 1. Main characteristics of the randomised trials included in the meta-analysis.
| TRIALS (first author) | YEAR | TREATMENT | TARGETED PATHWAY | Platinum status | PATI- ENTS | RR control arm | RR experimental arm | OS | PFS |
|---|---|---|---|---|---|---|---|---|---|
| (%) | (%) | HR | HR | ||||||
| Burger [9] | 2011 | BEVACIZUMAB+CHT vs CHT | angiogenesis | 1873 | NR | NR | 1.03 | 0.9 | |
| Perren [10] | 2011 | BEVACIZUMAB+CHT vs CHT | angiogenesis | 1528 | 48 | 67 | 0.64 | 0.73 | |
| Pujade-Lauraine [15] | 2014 | BEVACIZUMAB+CHT vs CHT | angiogenesis | resistant | 361 | 12 | 27 | 0.85 | 0.48 |
| Aghajanian [50] | 2012 | BEVACIZUMAB+CHT vs CHT | angiogenesis | sensitive | 484 | 57 | 79 | 1.02 | 0.48 |
| Gotlieb [51] | 2012 | AFLIBERCEPT vs PLB | angiogenesis | resistant | 55 | NR | NR | 1.02 | NR |
| Karlan [52] | 2012 | AMG386 10mg/kg+CHT vs CHT | angiogenesis | sens/resis | 108 | 27 | 37 | 0.6 | 0.81 |
| Karlan [52] | 2012 | AMG386 3mg/kg+CHT vs CHT | angiogenesis | sens/resis | 108 | 27 | 19 | 0.77 | 0.75 |
| Monk [53] | 2014 | AMG 386+CHT vs CHT | angiogenesis | resistant | 919 | 30 | 38 | 0.86 | 0.66 |
| Pignata [54] | 2015 | PAZOPANIB+CHT vs CHT | angiogenesis | resistant | 74 | 25 | 56 | 0.6 | 0.42 |
| Vergote [55] | 2013 | ENZASTAURIN+CHT vs CHT | angiogenesis | 142 | 39 | 43 | NR | 0.8 | |
| Raja [62] | 2013 | CEDIRANIB+CHT vs CHT | angiogenesis | sensitive | 456 | NR | NR | NR | 0.57 |
| Birrer [68] | 2013 | OMBRABULIN+CHT vs CHT | angiogenesis | sensitive | 154 | 71 | 65 | NR | 1.33 |
| Lorusso [67] | 2014 | NGR-hTNF+CHT vs CHT | angiogenesis | resistant | 109 | NR | NR | 0.7 | 1.08 |
| Hainsworth [70] | 2015 | SORAFENIB+CHT vs CHT | angiogenesis | 85 | 74 | 67 | NR | NR | |
| Coleman [74] | 2014 | VANDETANIB+CHT vs CHT | angiogenesis | resistant | 131 | 9 | 12 | 1.25 | 0.99 |
| Du Bois [75] | 2013 | BIBF 1120+CHT vs CHT | angiogenesis | 1366 | NR | NR | NR | 0.84 | |
| Kaye [56] | 2012 | OLAPARIB 200mg vs PLB | DNA repair | sens/resis | 65 | 18 | 25 | 0.66 | 0.91 |
| Kaye [56] | 2012 | OLAPARIB 400 mg vs PLB | DNA repair | sens/resis | 65 | 18 | 31 | 1.01 | 0.86 |
| Oza [63] | 2015 | OLAPARIB+CHT-OLAPARIB vs CHT | DNA repair | sensitive | 162 | 58 | 64 | 1.17 | 0.51 |
| Kummar [64] | 2015 | VELIPARIB+CHT vs CHT | DNA repair | resistant | 74 | 19 | 12 | NR | NR |
| Makhija [57] | 2010 | PERTUZUMAB+CHT vs CHT | EGFR | resistant | 130 | 5 | 14 | 0.91 | 0.66 |
| Kaye [58] | 2013 | PERTUZUMAB+CHT vs CHT | EGFR | sensitive | 149 | 59 | 61 | 1.02 | 1.16 |
| Kurzeder [65] | 2015 | PERTUZUMAB+CHt vs CHT | EGFR | resistant | 154 | NR | NR | NR | 0.74 |
| Liu [66] | 2014 | MM-121+CHT vs CHT | EGFR | resistant | 223 | 11 | 13 | 1 | 1.027 |
| Meier [59] | 2012 | LONAFARNIB+CHT vs CHT | miscellaneous | 105 | NR | NR | 0.62 | 0.78 | |
| Naumann [60] | 2013 | EC145+CHT vs CHT | miscellaneous | resistant | 149 | 12 | 18 | 1.01 | 0.63 |
| Cognetti [61] | 2015 | ZIBOTENTAN+CHT vs CHT | miscellaneous | sensitive | 120 | 59 | 38 | NR | 1.46 |
| Pujade-Lauraine [69] | 2013 | VOLASERTIB vs CHT | miscellaneous | resistant | 109 | 15 | 13 | NR | 1.01 |
| Konecny [71] | 2014 | GANITUMAB+CHT vs CHT | miscellaneous | 170 | NR | NR | NR | 1.22 | |
| Lhommè [72] | 2008 | VALSPODAR + CHT vs CHT | miscellaneous | 762 | 42 | 34 | 0.99 | 0.96 | |
| McNeish [73] | 2014 | SARACATINIB+CHT vs CTH | miscellaneous | resistant | 107 | 43 | 29 | 0.94 | 1 |
| Oza [76] | 2015 | AZD1775+CHT vs CHT | miscellaneous | sensitive | 121 | 76 | 81 | 0.55 |
Abbreviations: overall survival, OS; progression free survival, PFS; hazard ratio, HR; TT: target therapy; ST: standard therapy; chemotherapy, CHT; best supportive care, BSC; not reported, NR.